NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Tuesday that total revenues for its first fiscal quarter fell 16 percent while net income dropped 47 percent as the company "felt the full brunt of the severe, worldwide economic downturn,” President and CEO Bill Sullivan said in a statement.

For the quarter ended Jan. 31, 2009, Agilent's total revenues fell to $1.17 billion from $1.39 billion — "well below" the company's expectations, Sullivan said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.